Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website. I am focused on driving long-term durable growth across the organization by reshaping our business and portfolio strategy while instilling increased organizational and operational rigor. AI-driven drug development helps the industry deliver more molecules and innovation, demand will increase for Certara's core business, Model-Informed Drug Development or MIDD. In February, the ICH released ICH M15, providing guidance of the general principles for Model-Informed Drug Development, which establishes an overarching set of principles for the acceptance of MIDD applications by regulators globally.
In March, the FDA published guidance on the general consideration for the use of New Approach Methodologies or NAMs in drug development. For example, the qualification of our Simcyp software for the prediction of drug-to-drug interactions in the EMA required two years of engagement with participants representing all 27 member states. To our knowledge, Simcyp is the only mechanistic modeling software qualified in Europe at this critical level. First, we're focusing our business in accelerating long-term growth by exiting medical writing.
Second, we're reorganizing and aligning the company around two distinct growth areas, MIDD and discovery, which we call MID3 and accelerated clinical evidence, which we call ACE. Second, we are reorganizing the company into two groups to accelerate growth and better service our customers, MID3 and ACE. Total revenue for the three months ended March 31st, 2026 was $106.9 million, representing year-over-year growth of 1% on a reported basis. Software revenue was $49.7 million in the first quarter, which increased 7% over the prior year period on a reported basis.